NASDAQHealth CareBiotechnologySnapshot 2026-07-09
Reading SGP? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →QuarterlyIQ Insights · SGP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Maintain sufficient cash from IPO proceeds to fund planned operations through the fiscal year 2028.
Newly stated in 2025-Q4. Management disclosed that the IPO proceeds are expected to fund operations through 2028. Financials show negative operating income of $15.4M and net loss of $13.8M in 2026-Q1, indicating ongoing cash burn. The trajectory is consistent with the stated priority to maintain funding for operations through 2028.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Not enough signal yet.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“With the IPO proceeds, SpyGlass Pharma expects its current cash position to fund planned operations through 2028.”
2 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 50% for the rest of the cohort, n=3552).
Not investment advice. As of 2026-07-09.
